Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 07, 2023

MHC Class II-Restricted Antigen Presentation Is Required to Prevent Cytotoxic T-Cell Dysfunction by Blood-Borne Myeloids in Brain Tumors

Cancer Cell


Additional Info

Disclosure statements are available on the authors' profiles:

Cancer Cell
MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors
Cancer Cell 2022 Dec 30;[EPub Ahead of Print], M Kilian, R Sheinin, CL Tan, M Friedrich, C Krämer, A Kaminitz, K Sanghvi, K Lindner, YC Chih, F Cichon, B Richter, S Jung, K Jähne, M Ratliff, RM Prins, N Etminan, A von Deimling, W Wick, A Madi, L Bunse, M Platten

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Brain Cancer Center of Excellence

Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.

Further Reading